MGNX - Investigation Into MacroGenics (MGNX) Announced by Hagens Berman | Benzinga

SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ:MGNX) investors who suffered substantial losses to submit your losses now.

Visit: www.hbsslaw.com/investor-fraud/mgnx
Contact the Firm Now: MGNX@hbsslaw.com
   844-916-0895

Investigation into MacroGenics, Inc. (MGNX):

The current investigation scrutinizes the accuracy of MacroGenics' statements regarding data from its Phase 2 TAMARACK study of the antibody-drug conjugate MGC018, known as "vobra duo," in patients with metastatic castration-resistant prostate cancer (mCRPC).

On Apr. 3, 2024, MacroGenics released interim safety data from the TAMARACK study, as detailed in an abstract submitted to the American Society of Clinical Oncology on Feb. 6, 2024. The company stated, "Preliminary safety data from TAMARACK suggest that reducing the ...

MGNX) Announced by Hagens Berman>Full story available on Benzinga.com